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At a Glance Commentary
Scientific Knowledge on the Subject
Few studies have previously assessed the association between quantitative interferon gamma 
release assay (IGRA) results and tuberculosis (TB) incidence rates; all were restricted to only 
one test, the QuantiFERON Gold-In-Tube (QFT-GIT). While two studies have suggested that 
a QFT-GIT threshold of ≥4 IU/mL may improve prediction of incident TB, none were able to 
fully assess the potential impact of implementing higher thresholds on predictive values, or 
the proportion of incident cases missed by latent tuberculosis infection (LTBI) screening 
programmes. 
What This Study Adds to the Field
This is the first study to comprehensively assess the potential impact of implementing higher 
diagnostic thresholds for all three available LTBI tests (tuberculin skin test (TST), QFT-GIT 
and T-SPOT.TB). We demonstrate that TB incidence rates increase incrementally with the 
magnitude of the T cell recall response for all three tests. However, while implementing higher 
thresholds leads to modest improvement in positive predictive value of these tests for incident 
TB, this benefit is offset by a marked loss in sensitivity, with the majority of incident TB cases 
being missed. Implementing higher diagnostic thresholds for the TST and commercial IGRAs 
is therefore unlikely to be of value for LTBI screening programmes in settings aiming towards 
TB elimination.
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Abstract
Rationale: Development of diagnostic tools with improved predictive value for tuberculosis 
(TB) is a global research priority. 
Objectives: We evaluated whether implementing higher diagnostic thresholds than currently 
recommended for QuantiFERON Gold-in-Tube (QFT-GIT), T-SPOT.TB and the tuberculin 
skin test (TST) might improve prediction of incident TB. 
Methods: Follow-up of a UK cohort of 9,610 adult TB contacts and recent migrants was 
extended by re-linkage to national TB surveillance records (median follow-up 4.7 years). 
Incidence rates and rate ratios, sensitivities, specificities and predictive values for incident TB 
were calculated according to ordinal strata for quantitative results of QFT-GIT, T-SPOT.TB 
and TST (with adjustment for prior BCG).
Measurements and Main Results: For all tests, incidence rates and rate ratios increased with 
the magnitude of the test result (p<0.0001). Over three years’ follow-up, there was a modest 
increase in positive predictive value (PPV) with the higher thresholds (3.0% for QFT-GIT ≥0.35 
IU/mL vs. 3.6% for ≥4.00 IU/mL; 3.4% for T-SPOT.TB ≥5 spots vs. 5.0% for ≥50 spots; and 
3.1% for BCG-adjusted TST ≥5mm vs. 4.3% for ≥15mm). As thresholds increased, sensitivity 
to detect incident TB waned for all tests (61.0% for QFT-GIT ≥0.35 IU/mL vs. 23.2% for ≥4.00 
IU/mL; 65.4% for T-SPOT.TB ≥5 spots vs. 27.2% for ≥50 spots; 69.7% for BCG-adjusted TST 
≥5mm vs. 28.1% for ≥15mm).
Conclusions: Implementation of higher thresholds for QFT-GIT, T-SPOT.TB and TST 
modestly increases PPV for incident TB, but markedly reduces sensitivity. Novel biomarkers 
or validated multivariable risk algorithms are required to improve prediction of incident TB. 
Words: 250
Keywords: latent tuberculosis; epidemiology; screening; quantiferon; t-spot.tb
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Introduction
Treatment for latent tuberculosis infection (LTBI) reduces the risk of progression to 
tuberculosis (TB) disease, and thus offers an opportunity to prevent TB-related morbidity, 
while also interrupting onward transmission(1). Scaling up testing and treatment for LTBI 
among TB risk groups is therefore an integral component of the World Health Organization 
(WHO) End TB Strategy(2, 3). However, the effectiveness of LTBI screening programmes is 
undermined by the poor positive predictive value of currently available LTBI diagnostic tests 
for incident TB disease, which is <5% for both the tuberculin skin test (TST) and commercial 
interferon gamma release assays (IGRAs) over a two year period(4–6). As a result, the 
majority of individuals with a positive TST or IGRA will never develop TB disease. This leads 
to a large burden of unnecessary LTBI treatment, with associated risks of drug toxicity to 
patients, and economic costs to health services. Furthermore, poor predictive value may also 
undermine the uptake of LTBI treatment among target groups, due to the low perceived risk 
of TB(7). The WHO have therefore highlighted the development of novel biomarkers with 
better predictive value as a key research and development priority in a target product profile 
(TPP) consensus document, stating optimal performance criteria of sensitivity and specificity 
90%(8).
Recent emerging data from studies in both adults and infants in low and high TB incidence 
settings have demonstrated that higher quantitative IGRA results are associated with 
increased risk of incident TB, thus raising hope that IGRAs themselves may go some way to 
fulfilling the WHO TPP(9–11). Moreover, since current diagnostic thresholds for scoring a 
positive test are based on detecting sensitisation to M. tuberculosis rather than development 
of incident TB disease, optimising these thresholds might lead to improved implementation of 
existing LTBI diagnostics, while novel biomarkers with improved predictive value are awaited. 
However, previous evaluations of quantitative IGRA results have been limited to the 
QuantiFERON Gold-In-Tube (QFT-GIT) assay only(9–13), and it remains unclear whether 
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implementation of a higher threshold for positivity may actually be of use in clinical practice to 
improve the risk-stratification of patients with LTBI. 
We sought to address these key knowledge gaps by extending follow-up of participants in the 
UK Prognostic Evaluation of Diagnostic IGRAs Consortium (UK PREDICT) TB study(6). 
Firstly, we aimed to test the hypothesis that higher quantitative QFT-GIT, T-SPOT.TB and 
TST results were associated with increased risk of incident TB. Secondly, we sought to 
evaluate the test sensitivities, specificities and predictive values when higher thresholds for a 
positive test than currently recommended are used over a fixed three-year follow-up period. 
Finally, we plotted receiver operating characteristic (ROC) curves for all three tests, to 
compare performance across the full range of test cut-offs. Some of the results of this study 
have been previously reported in the form of an abstract(14).
Methods
Population
The UK PREDICT study cohort has been described in detail previously(6). Briefly, individuals 
aged ≥16 years were recruited (01/05/2010-30/06/2015) from London, Birmingham and 
Leicester. Inclusion criteria were: recent contacts of patients with active TB; or recent migrants 
from, or prolonged travellers to, high TB burden countries. Participants treated for LTBI were 
excluded, as were participants diagnosed with suspected baseline prevalent TB (evidence of 
TB within 21 days of enrolment). 
Study procedures
Participants were tested with QFT-GIT (Qiagen, Venlo, The Netherlands), T-SPOT.TB (Oxford 
Immunotec, UK) and then Mantoux TST (Statens Serum Institut) using standardised protocols 
on the same day, at least 6 weeks from last TB exposure or migration. Indeterminate results 
were classified as recommended by the manufacturers (Online Data Supplement). Incident 
TB cases were identified via telephone interview at 12 and 24 months, and by linkage to the 
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national TB surveillance system held at Public Health England, which includes all statutory TB 
notifications and all results of positive M. tuberculosis cultures. For this analysis, all 
participants were re-linked to national TB surveillance records to identify individuals notified 
with TB until 31/12/2017. Follow-up was censored on the earliest of date of TB diagnosis, 
death or 31/12/2017. The study procedures and protocol were approved by the Brent NHS 
Research Ethics Committee (10/H0717/14). 
Statistical Analysis
Incidence rates and ratios relative to the negative test category (with 95% confidence intervals 
(CIs)) for incident TB were calculated using Poisson models, according to ordinal strata for 
quantitative results of each LTBI test during the full duration of follow-up. For participants with 
previous BCG vaccination (defined by self-report and scar inspection), 10mm was subtracted 
from the quantitative TST result to adjust for the associated sensitisation to BCG (‘BCG-
adjusted TST’). The rationale for this was that, in the main UK PREDICT analysis, a BCG-
stratified TST cut-off of 5mm in BCG-naïve or 15mm in vaccinated participants performed 
similarly to IGRA(6). For QFT-GIT and BCG-adjusted TST, test strata were based on previous 
data(9, 10, 15–17). For QFT-GIT, these were TB antigen interferon-γ minus unstimulated 
control interferon-γ levels of <0.35 IU/mL, 0.35–0.69 IU/mL, 0.7-3.99 IU/mL and ≥4.00 IU/mL. 
For BCG-adjusted TST, the strata used were <5mm, 5-9mm, 10-14mm and ≥15mm 
induration.
For T-SPOT.TB, no previous data were available to inform the test strata examined. We chose 
initial strata of spot counts in the maximal TB antigen panel minus the negative control of ≤4 
spots and 5-7 spots, based on manufacturer test thresholds for borderline and positive results, 
and used restricted cubic spline models to investigate the non-linear association between 
quantitative T-SPOT.TB results and incident TB risk (Online Data Supplement). Informed by 
visualisation of these models, we defined further strata of spot counts in the maximal TB 
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antigen panel minus the negative control of 8-49 spots and ≥50 spots (corresponding 
approximately to the top 5% of quantitative T-SPOT.TB results in the cohort). 
Sensitivity, specificity, positive and negative predictive values and receiver operating 
characteristic (ROC) curves for incident TB over a fixed three-year follow-up period were 
calculated at the corresponding thresholds for each stratum. 
Seven sensitivity analyses were performed, as detailed in the Online Data Supplement. All 
analyses were performed using Stata version 15. 
Results
A total of 10,045 participants were recruited to the study. Of these, 175 had possible prevalent 
TB at baseline and a further 260 were treated for LTBI. The remaining 9,610 were therefore 
included in the final study cohort, with median follow-up 4.7 years (interquartile range (IQR) 
3.8-5.5). Baseline characteristics of the cohort are summarised in Table 1. A total of 
5,526/9,610 (57.5%) participants were aged <35 years. The cohort included 4,781 (49.8%) 
recent TB contacts and 4,729 (49.2%) migrants from high-incidence countries, while 
6,618/9,610 (68.9%) reported previous BCG vaccination. A total of 8,562 (89.1%), 8,079 
(84.1%) and 7,833 (81.5%) of participants had available quantitative QFT-GIT, T-SPOT.TB 
and TST results, respectively. A total of 107 participants progressed to incident TB during 
follow-up, of which 47 (43.9%) had pulmonary involvement, and 59 (55.1%) were 
microbiologically confirmed by either culture or PCR. Median time to TB disease among the 
progressors was 188 days (IQR 76 – 488 days). A total of 71 (66.4%), 19 (17.8%) and 5 (4.7%) 
participants progressed during the first, second and third years of follow-up, respectively. The 
distributions of quantitative QFT-GIT, T-SPOT.TB and BCG-adjusted TST results, stratified by 
the development of incident TB, are shown in Figure 1. 
Indeterminate results contributed 122/8,562 (1.4%) QFT-GIT results, and 121/8,079 (1.5%) T-
SPOT.TB results. Of those with available results, 6,637 (77.5%), 405 (4.7%), 820 (9.6%) and 
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578 (6.8%) had QFT-GIT results in the <0.35 IU/mL, 0.35–0.69 IU/mL, 0.7-3.99 IU/mL and 
≥4.00 IU/mL strata, respectively. For T-SPOT.TB, 6,290 (77.9%), 319 (3.9%), 906 (11.4%) 
and 443 (5.6%) of participants had results in the ≤4 spots, 5-7 spots, 8-49 spots and ≥50 spots 
strata, respectively. For BCG-adjusted TST, 5,769 (73.7%), 827 (10.6%), 630 (8.0%), and 607 
(7.75%) had induration in the <5mm, 5-9mm, 10-14mm and ≥15mm strata, respectively. 
Duration of follow-up was similar between participants in different test strata (Figure 2). 
For all tests, TB incidence rates and ratios increased with the magnitude of the test response 
(Figure 2). For QFT-GIT, TB incidence rates (per 1,000 person-years) increased from 1.10 
(95% CI 0.78 - 1.53) in the <0.35 IU/mL stratum, to 10.02 (6.82 - 14.72) in the ≥4.00 IU/mL 
stratum (likelihood ratio test for trend p<0.0001). For T-SPOT.TB, TB incidence rates 
increased from 1.10 (0.78 - 1.54) in the ≤4 spots stratum to 12.73 (8.73 - 18.57) in the ≥50 
spots stratum (p<0.0001). For the BCG-adjusted TST, TB incidence rates increased from 1.07 
(0.75 - 1.54) in the <5mm stratum to 10.95 (7.70 - 15.57) in the ≥15mm stratum (p<0.0001). 
Considering diagnostic test performance for the prediction of incident TB in the first three years 
of follow-up, positive predictive values (PPV) were uniformly low but increased modestly with 
the higher thresholds for all three tests (Table 2). PPVs were 3.0% (2.2 - 3.9) for QFT-GIT 
≥0.35 IU/mL vs. 3.6% (2.2 - 5.5) for ≥4.00 IU/mL; 3.4% (2.6 - 4.4) for T-SPOT.TB ≥5 spots vs. 
5.0% (3.2 - 7.5) for ≥50 spots; and 3.1% (2.4 - 4.0) for BCG-adjusted TST ≥5mm vs. 4.3% (2.8 
- 6.2) for ≥15mm. However, as thresholds for test positivity increased, sensitivity declined for 
all tests (Table 2). For the QFT-GIT, sensitivity decreased from 61.0% (95% CI 49.6 - 71.6) 
with a threshold ≥0.35 to 23.2% (14.6 - 33.8) with a threshold ≥4.00 IU/mL. For T-SPOT.TB, 
sensitivity decreased from 65.4% (54.0 - 75.7) with a threshold ≥5 spots to 27.2% (17.9 - 38.2) 
with a threshold ≥50 spots. For BCG-adjusted TST, sensitivity was 69.7% (59.0 - 79.0) with a 
threshold ≥5mm, but only 28.1% (19.1 - 38.6) with a threshold ≥15mm.
ROC curve analysis revealed similar AUROCs of 0.77 (95% CI 0.72 - 0.82), 0.78 (0.72 - 0.83) 
and 0.74 (0.69 - 0.79) for QFT-GIT, T-SPOT.TB and BCG-adjusted TST for predicting incident 
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TB over three years’ follow-up, respectively (Figure 3). Paired DeLong tests(18) revealed no 
difference in AUROCs for QFT-GIT (p=0.21) or BCG-adjusted TST (p=0.14), when compared 
to T-SPOT.TB. 
In the sensitivity analyses (Online Data Supplement), exclusion of incident TB cases <42 days 
from enrolment resulted in slightly lower TB incidence rates across all strata, but had little 
impact on IRRs between strata. Similarly, the sub-analyses restricted to TB contacts and 
migrants revealed lower TB incidence rates overall among migrants compared to TB contacts, 
but little difference in IRRs between strata for each test. Analysis of participants with 
indeterminate results revealed that only a small number of incident cases for both the QFT-
GIT (n=3) and T-SPOT.TB (n=2), precluding further analysis. Inclusion of a fifth stratum for 
QFT-GIT (≥8 IU/mL) had no effect in increasing incidence rates further. Including fifth strata 
for T-SPOT.TB and BCG-adjusted TST (≥100 spots for T-SPOT.TB; ≥20mm for BCG-adjusted 
TST) led to further increases in the incidence rates in these strata. However, as for the main 
analysis, there was a further loss of sensitivity when implementing corresponding diagnostic 
thresholds. Analysis of quantitative TST results without subtracting the 10mm deduction for 
participants who reported BCG vaccination resulted in lower incidence rates in all strata, 
compared with the primary analysis, without changing the overall pattern observed. Limiting 
follow-up to six months produced similar sensitivity, specificity and predictive value results to 
the main analysis. Finally, associations between quantitative test results and incident TB in 
multivariable Poisson models adjusted for age, gender, ethnicity, country of birth and 
indication for screening (recent contact vs. migration) were similar to the primary univariable 
analyses. 
Discussion
We have demonstrated that higher quantitative results for the QFT-GIT, T-SPOT.TB and TST 
were strongly associated with higher TB incidence rates, supporting existing data derived 
among adult and paediatric populations, from low and high TB incidence settings respectively 
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(9–11). This is the first study, however, to comprehensively assess the potential impact of 
implementing higher diagnostic thresholds for all three tests, using a uniquely powerful and 
well-characterised cohort. We found that implementing higher thresholds would lead to a 
marked loss of sensitivity for all three tests, whereby the majority of incident TB cases would 
test negative. A modest loss of test sensitivity may be acceptable in some circumstances, 
where the programmatic goal is to identify the subgroup with the highest risk of progression, 
if it is accompanied by a substantial improvement in PPV. However, PPV for all three tests 
remained ≤5%, even in the highest strata. While this is likely partly a reflection of the low pre-
test probability of incident TB in low TB incidence settings (such as the UK), even among risk 
groups such as TB contacts and recent migrants, it also highlights the limitations of our existing 
diagnostic tests for predicting incident TB. Our previous analysis showed that TST stratified 
by BCG status yielded comparable performance to both commercial IGRAs(6). Our ROC 
curve data in the current analysis reinforces this conclusion, as AUROCs were very similar for 
all three tests, with overlapping 95% confidence intervals. 
These data demonstrate that implementing higher diagnostic thresholds for QFT-GIT, T-
SPOT.TB and TST is unlikely to be of use in settings aiming towards TB elimination, and fails 
to bridge the gap to the WHO TPP for biomarkers with greater predictive value for incident TB. 
One approach may be to offer preventative therapy to all patients with positive LTBI tests, 
using current thresholds, with the offer of additional support to complete treatment to those 
with higher quantitative results, who are at highest risk of disease. However, such an approach 
should ensure that current resources are not diverted away from supporting those with lower 
quantitative positive test results to commence and complete preventative therapy, since doing 
so would risk missing the majority of progressors. 
Although our findings support the hypothesis that quantitative measures of T cell recall (as 
measured by IGRAs and the TST) are correlates of risk of disease, which may reflect 
underlying mycobacterial burden, test sensitivity for incident TB cases was only 61.0 - 69.7% 
when using conventional thresholds over three years’ follow-up. This finding is consistent with 
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recent data demonstrating IGRA sensitivity of 67-81%, even among prevalent TB cases(19). 
A negative IGRA in these examples may be a consequence of susceptibility to TB disease 
among a subgroup of exposed individuals who either fail to mount any adaptive immune 
response to M. tuberculosis, develop an immune response that is independent of interferon-
gamma(20), or have a localised response in tissue compartments that is not reflected in blood. 
Furthermore, in contrast to the hypothesis that a positive IGRA or TST are correlates of risk, 
cases of Mendelian susceptibility to mycobacterial disease show that Th1 responses which 
underpin IGRAs and the TST are necessary for protection against TB(21). This contradiction 
reflects the fact that interferon-gamma polarised T cell responses do not discriminate between 
immunological protection and immunopathogenesis. Thus, these measures should be 
considered as imperfect correlates of risk when used for TB diagnosis, prognostication, or as 
outcome measures in vaccine efficacy studies(22).
This study reinforces an ongoing need for novel biomarkers that predict progression to incident 
TB more accurately, in order to facilitate precision delivery of therapy for LTBI to those who 
need it most, and thereby reduce the number needed to treat. While IGRAs and the TST aim 
to detect immune sensitisation to TB, it is increasingly recognised that tests that better 
delineate the spectrum of LTBI will be required to improve predictive value(23). One such 
example is whole-blood host transcriptional signatures, which have demonstrated promise for 
the detection of ‘incipient’, or subclinical, TB (24–27). However, a validated biomarker that 
achieves the WHO TPP for the prediction of incident TB has not yet been identified. In the 
interim, ensuring optimal implementation of existing LTBI tests is of paramount importance. 
While higher diagnostic thresholds for QFT-GIT, T-SPOT.TB and TST may not address this 
in isolation, inclusion of these quantitative results in a multivariable clinical risk model may 
improve prediction of incident TB, though existing tools remain unvalidated(4, 28). 
This study has a number of strengths. Firstly, it is a very large scale (n=9,610), prospective 
study with lengthy median follow-up of almost five years, and robust identification of incident 
TB cases, including by linkage to national TB surveillance records. The study population, 
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consisting of UK recent TB contacts and migrants from high TB incidence settings, is well 
characterised and highly representative of target groups for LTBI screening programmes in 
low TB incidence settings(3). Our findings are therefore likely to be generalizable to other low 
TB incidence countries. Furthermore, availability of diagnostic test results was very high, with 
QFT-GIT, T-SPOT.TB and TST results available for 8,562 (89.1%), 8,079 (84.1%) and 7,833 
(81.5%) of participants, respectively, while the inclusion of a large number of both TB contacts 
and recent migrants facilitated robust sensitivity analyses restricted to each sub-population. 
A limitation was that an updated version of the QFT-GIT (QuantiFERON-TB Gold Plus; 
Qiagen, Venlo, The Netherlands), which became available late in the follow-up period, was 
not assessed in this study(29). Prospective evaluations of the predictive value of this assay 
for incident TB are required. Secondly, a positive LTBI test, done as part of the study, could 
potentially have led to differential reporting bias, as a positive result may have increased 
clinical suspicion of TB and therefore led to more TB diagnoses among participants with a 
positive test. However, test results were available to participants’ clinicians only for TB 
contacts aged ≤35 years since, during the study period, these were the only participants who 
met NICE criteria for LTBI testing(15). The magnitude of this bias is therefore likely to be small. 
Thirdly, only baseline testing was performed. We are therefore unable to assess conversions 
or reversions during serial testing, which may be frequent(30). Since the reality of both contact 
and migrant LTBI screening programmes is that serial testing (beyond 6 weeks post-contact) 
is highly unlikely to be cost-effective, this limitation reflects the constraints of routine 
programmatic conditions; the ability of the tests to identify progressors at the point of initial 
screening is therefore a key attribute. Finally, we are also unable to account for any further TB 
exposure events between recruitment and diagnosis, which may have led us to underestimate 
test sensitivity. However, 66.4% of progression events occurred in the first year (median time 
to disease 188 days), and there is a generally low risk of TB transmission in the UK. Moreover, 
test sensitivity when using conventional thresholds remained 57.8-79.6% when follow-up was 
limited to six months; the impact of this bias is therefore likely small. 
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In conclusion, optimal implementation of existing LTBI diagnostic tests is critical while we 
continue to develop novel commercial assays with improved predictive value. While higher 
quantitative QFT-GIT, T-SPOT.TB and TST results were associated with higher TB incidence 
rates in this study, the implementation of higher diagnostic thresholds for these tests comes 
at the cost of a marked loss of sensitivity, such that only a minority of incident TB cases are 
detected. Moreover, the improvement in PPV with higher test thresholds was modest. 
Incorporation of quantitative results into validated multivariable risk prediction models may be 
of use to further improve prediction of incident TB in the short-to-medium term. However, a 
better biomarker is ultimately required to transform risk stratification of patients with LTBI. 
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Figure Legends
Figure 1: Cumulative distribution plots showing distribution of quantitative test results for the 
QuantiFERON Gold-In-Tube (QFT-GIT), T-SPOT.TB and BCG-adjusted tuberculin skin test 
(TST), stratified by whether participants progressed to incident TB during follow-up. Dashed 
lines indicate thresholds used in this analysis. 
Figure 2: Tuberculosis (TB) incidence rates and ratios in ordinal strata for quantitative results 
of QuantiFERON Gold-In-Tube (QFT-GIT), T-SPOT.TB and BCG-adjusted TST. P values 
indicate likelihood ratio tests for trend. CI = confidence interval; IRR = incidence rate ratio; IQR 
= interquartile range. Data also presented as a table in Online Data Supplement. 
Figure 3: Receiver operating characteristic curves for prediction of incident tuberculosis (TB) 
during three years’ follow-up by quantitative QuantiFERON Gold-In-Tube (QFT-GIT), T-
SPOT.TB and BCG-adjusted tuberculin skin test results. AUC = area under the curve. 95% 
confidence intervals indicated in brackets.
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Table 1: Baseline characteristics of UK PREDICT TB cohort, stratified by whether or not 
participants progressed to incident TB during follow-up. TB = tuberculosis; IQR = interquartile 
range; CI = confidence interval; QFT-GIT = QuantiFERON Gold-In-Tube; TST = tuberculin 
skin test. Data are presented as n (%) or median (IQR). 
TB-free TB progressors Total
Sex
Male 4673 (49.2) 56 (52.3) 4729 (49.2)
Female 4758 (50.1) 51 (47.7) 4809 (50)
Missing 72 (0.8) 0 (0) 72 (0.7)
Age
≤35 5455 (57.4) 71 (66.4) 5526 (57.5)
>35 4026 (42.4) 36 (33.6) 4062 (42.3)
Missing 22 (0.2) 0 (0) 22 (0.2)
Median (IQR) 33 (26-47) 30 (26-39) 33 (26-47)
Ethnicity
Indian 3939 (41.5) 42 (39.3) 3981 (41.4)
White 1161 (12.2) 12 (11.2) 1173 (12.2)
Black African 1126 (11.8) 12 (11.2) 1138 (11.8)
Mixed 881 (9.3) 11 (10.3) 892 (9.3)
Pakistani 891 (9.4) 15 (14) 906 (9.4)
Bangladeshi 712 (7.5) 4 (3.7) 716 (7.5)
Black Caribbean 237 (2.5) 5 (4.7) 242 (2.5)
Other 315 (3.3) 5 (4.7) 320 (3.3)
Missing 241 (2.5) 1 (0.9) 242 (2.5)
UK Born
No 7917 (83.3) 91 (85) 8008 (83.3)
Yes 1536 (16.2) 16 (15) 1552 (16.1)
Missing 50 (0.5) 0 (0) 50 (0.5)
Contact or migrant
Contact 4711 (49.6) 70 (65.4) 4781 (49.8)
Migrant 4692 (49.4) 37 (34.6) 4729 (49.2)
Missing 100 (1.1) 0 (0) 100 (1)
BCG vaccinated
No 1457 (15.3) 13 (12.1) 1470 (15.3)
Yes 6538 (68.8) 80 (74.8) 6618 (68.9)
Missing 1508 (15.9) 14 (13.1) 1522 (15.8)
QFT-GIT
<0.35 6603 (69.5) 34 (31.8) 6637 (69.1)
0.35-0.69 398 (4.2) 7 (6.5) 405 (4.2)
0.7-3.99 793 (8.3) 27 (25.2) 820 (8.5)
≥4 552 (5.8) 26 (24.3) 578 (6)
Indeterminate 119 (1.3) 3 (2.8) 122 (1.3)
Missing 1038 (10.9) 10 (9.3) 1048 (10.9)
T-SPOT.TB
<5 6257 (65.8) 33 (30.8) 6290 (65.5)
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5 to 7 316 (3.3) 3 (2.8) 319 (3.3)
8 to 49 876 (9.2) 30 (28) 906 (9.4)
≥50 416 (4.4) 27 (25.2) 443 (4.6)
Indeterminate 119 (1.3) 2 (1.9) 121 (1.3)
Missing 1519 (16) 12 (11.2) 1531 (15.9)
BCG-adjusted TST* (mm)
<5 5739 (60.4) 30 (28) 5769 (60)
5 to 9 805 (8.5) 22 (20.6) 827 (8.6)
10 to 14 612 (6.4) 18 (16.8) 630 (6.6)
≥15 576 (6.1) 31 (29) 607 (6.3)
Missing 1771 (18.6) 6 (5.6) 1777 (18.5)
Follow-up (years)
Median (IQR) 4.69 (3.82-5.52) 0.51 (0.21-1.34) 4.68 (3.78-5.51)
Total 9503 107 9610
*For participants with previous BCG vaccination (defined by self-report and scar inspection), 
10mm was deducted from the quantitative TST result to adjust for the associated 
sensitisation to BCG (‘BCG-adjusted TST’) 
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Table 2: Sensitivity, specificity, positive predictive values and negative predictive values during three years’ follow-up with pre-specified test 
thresholds. CI = confidence interval; QFT-GIT = QuantiFERON Gold-In-Tube; TST = tuberculin skin test; n = numerator; N = denominator. 
QFT-GIT (IU/mL) T-SPOT.TB (spots) BCG-adjusted TST* (mm)
≥0.35 ≥0.7 ≥4 ≥5 ≥8 ≥50 ≥5 ≥10 ≥15
Sensitivity n 50 44 19 53 50 22 62 42 25
N 82 82 82 81 81 81 89 89 89
Estimate 61.0% 53.7% 23.2% 65.4% 61.7% 27.2% 69.7% 47.2% 28.1%
95% CI (49.6-71.6) (42.3-64.7) (14.6-33.8) (54-75.7) (50.3-72.3) (17.9-38.2) (59-79) (36.5-58.1) (19.1-38.6)
Specificity n 6134 6511 7242 5856 6155 6948 5520 6295 6882
N 7755 7755 7755 7363 7363 7363 7445 7445 7445
Estimate 79.1% 84.0% 93.4% 79.5% 83.6% 94.4% 74.1% 84.6% 92.4%
95% CI (78.2-80) (83.1-84.8) (92.8-93.9) (78.6-80.4) (82.7-84.4) (93.8-94.9) (73.1-75.1) (83.7-85.4) (91.8-93)
Positive predictive value n 50 44 19 53 50 22 62 42 25
N 1671 1288 532 1560 1258 437 1987 1192 588
Estimate 3.0% 3.4% 3.6% 3.4% 4.0% 5.0% 3.1% 3.5% 4.3%
95% CI (2.2-3.9) (2.5-4.6) (2.2-5.5) (2.6-4.4) (3-5.2) (3.2-7.5) (2.4-4) (2.6-4.7) (2.8-6.2)
Negative predictive value n 6134 6511 7242 5856 6155 6948 5520 6295 6882
N 6166 6549 7305 5884 6186 7007 5547 6342 6946
Estimate 99.5% 99.4% 99.1% 99.5% 99.5% 99.2% 99.5% 99.3% 99.1%
95% CI (99.3-99.6) (99.2-99.6) (98.9-99.3) (99.3-99.7) (99.3-99.7) (98.9-99.4) (99.3-99.7) (99-99.5) (98.8-99.3)
*For participants with previous BCG vaccination (defined by self-report and scar inspection), 10mm was deducted from the quantitative TST 
result to adjust for the associated sensitisation to BCG (‘BCG-adjusted TST’)
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S1: Definitions of indeterminate test results
QFT-GIT and T-SPOT.TB were classified as per the manufacturers’ guidance, following the algorithms 
below. 
Indeterminate QFT-GIT: 
 TB antigen minus negative control <0.35 IU/mL with positive control minus negative 
control <0.5 IU/mL; OR
 TB antigen minus negative control ≥0.35 IU/mL & <25% of negative control with positive 
control minus negative control <0.5 IU/mL; OR 
 negative control >8.0 IU/mL. 
Indeterminate T-SPOT.TB: 
 >10 spots in the negative control panel; OR
 <20 spots in the positive control panel. 
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S2: Further details of restricted cubic splines models, modelling approach and sensitivity 
analyses
Since no previous data were available to inform the definition of test strata for T-SPOT.TB, we modelled 
the non-linear relationship between the maximal T-SPOT.TB antigen minus negative control result and 
probability of incident TB within three years using restricted cubic splines logistic regression models. 
This analysis was performed in Stata version 15, using the ’postrcspline’ package. We developed two 
models: (A) knots at 8 (based on the manufacturer threshold for positivity), 50 and 100 (based 
approximately on the 95th and 97.5th centiles, respectively); and (B) knots at 6, 20 and 110, based 
approximately on the 10th, 50th and 90th centiles for participants with T-SPOT.TB results ≥5 (the 
threshold for a ’borderline’ result). Both models produced similar results (Supplementary Figure 1), and 
showed reasonable fit when compared visually with the raw data (Supplementary Table 1). These 
models therefore informed our selection of ≥50 spots as the highest stratum in the primary analysis, 
and ≥100 spots as the highest stratum in the sensitivity analysis. 
Seven sensitivity analyses were performed:
a) A prevalent TB case (excluded from the analysis) was defined as a TB case diagnosed <42 
days from enrolment (versus <21 days in the primary analysis). 
b) Sub-analyses were performed restricted to only contacts and migrants, respectively. 
c) A fifth stratum was also included for each diagnostic test (≥8·00 IU/mL for QFT-GIT; ≥100 spots 
for T-SPOT.TB (based on restricted cubic splines model); ≥20mm for BCG-adjusted TST), due 
to the arbitrary nature of the defined thresholds. 
d) TB incidence rates among subjects with indeterminate results were also examined.  
e) Quantitative TST results were analysed without subtracting the 10mm deduction for participants 
who reported BCG vaccination. 
f) We recalculated sensitivity, specificity and predictive values for a fixed follow-up period of six 
months to assess test performance for predicting short-term risk of progression.
g) In the primary analysis, we intentionally did not perform a multivariable analysis to assess 
whether higher quantitative test results remained independently associated with risk of incident 
TB following adjustment for other co-variates. The rationale for this is that our aim was to assess 
the potential programmatic impact of implementing higher diagnostic thresholds alone among 
target groups for LTBI screening programmes, rather than developing a multivariable risk 
prediction model. However, we examined associations between quantitative test results and 
incident TB in multivariable Poisson models adjusted for age, gender, ethnicity, country of birth 
and indication for screening (recent contact vs. migration) as a sensitivity analysis. 
Page 33 of 46  AJRCCM Articles in Press. Published on 11-December-2019 as 10.1164/rccm.201905-0969OC 
 Copyright © 2019 by the American Thoracic Society 
Supplementary Figure 1: Restricted cubic splines models to examine the non-linear association 
between quantitative T-SPOT.TB results and probability of incident TB within three years’ follow-up, 
using logistic regression models. Blue shaded area indicates 95% confidence intervals.
Model 1 (knots at 8, 50 and 100 spots)
Model 2 (knots at 6, 20 and 110 spots)
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Supplementary Table 1: Raw data showing risk of incident TB within three years’ follow-up in ordinal 
T-SPOT.TB strata based on deciles of quantitative results for participants with a result >0 spots. 
These raw data facilitate visual comparison with restricted cubic splines models shown in 
Supplementary Figure 1 above. TB risk shown as % (95% confidence interval). 
T-SPOT.TB (Spots) No TB TB TB risk (95% CI) All
0 3863 12 0.3 (0.2-0.5) 3875
1 1192 8 0.7 (0.3-1.3) 1200
2 418 3 0.7 (0.1-2.1) 421
3 to 5 501 5 1 (0.3-2.3) 506
6 to 10 356 10 2.7 (1.3-5) 366
11 to 23 335 7 2 (0.8-4.2) 342
24 to 57 334 17 4.8 (2.8-7.6) 351
≥58 364 19 5.0 (3-7.6) 383
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S3: Tuberculosis (TB) incidence rates and ratios in ordinal strata for quantitative results of QuantiFERON Gold-In-Tube (QFT-GIT), T-SPOT.TB and 
BCG-adjusted TST. 
Supplementary Table 2: Table of tuberculosis (TB) incidence rates and ratios in ordinal strata for quantitative results of QuantiFERON Gold-In-Tube (QFT-
GIT), T-SPOT.TB and BCG-adjusted TST. P values indicate likelihood ratio tests for trend. CI = confidence interval; IRR = incidence rate ratio; IQR = 
interquartile range. Data shown graphically in Figure 2 in main manuscript. 
QFT-GIT T-SPOT.TB BCG-adjusted TST
<0.35 0.35-0.69 0.7-3.99 ≥4 <5 5 to 7 8 to 49 ≥50 <5 5 to 9 10 to 14 ≥15
TB cases 34 7 27 26 33 3 30 27 30 22 18 31
Person-years 
(1,000s)
31.05 1.90 3.80 2.59 30.07 1.54 4.15 2.12 27.91 3.94 3.03 2.83
IR (per 1,000) 1.10 3.68 7.10 10.02 1.10 1.95 7.23 12.73 1.07 5.58 5.95 10.95
95% CI (0.78-1.53) (1.75-7.71) (4.87-10.35) (6.82-14.72) (0.78-1.54) (0.63-6.06) (5.06-10.35) (8.73-18.57) (0.75-1.54) (3.67-8.47) (3.75-9.44) (7.7-15.57)
IRR ref 3.36 6.48 9.15 ref 1.78 6.59 11.60 ref 5.19 5.54 10.19
95% CI (1.49-7.57) (3.91-10.74) (5.49-15.25) (0.55-5.80) (4.02-10.81) (6.98-19.3) (3.00-9.00) (3.09-9.93) (6.17-16.84)
Follow-up 
(median years)
4.78 4.82 4.78 4.57 4.88 4.92 4.68 4.99 4.92 4.92 5.00 4.77
IQR (3.93-5.53) (4.01- 5.53) (3.98- 5.57) (3.69-5.45) (4.05-5.59) (4.16-5.59) (3.87-5.55) (4.36-5.68) (4.14-5.62) (4.10-5.63) (4.12-5.63) (4.11-5.56)
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S4: Sensitivity analysis (a): Alternative definition of ‘prevalent’ tuberculosis (<42 days from 
enrolment)
Supplementary Table 3: Estimates of incidence rates of TB according to test strata under sensitivity 
analysis in which cases of prevalent TB are defined as those <42 days from enrolment and excluded, 
in comparison to results of primary analysis (with prevalent TB defined as <21 days from enrolment). 
IR = incidence rate; CI = confidence intervals. 
QFT-GIT (IU/mL) TB cases Person-years 
(1,000s)
IR (per 1,000) 95% CI
<0.35 28 31.05 0.90 0.62 - 1.31
0.35-0.69 6 1.90 3.15 1.42 - 7.02
0.7-3.99 25 3.80 6.57 4.44 - 9.72
≥4 23 2.59 8.87 5.89 - 13.34
T-SPOT.TB (spots)
<5 31 30.07 1.03 0.72 - 1.47
5 to 7 2 1.54 1.30 0.33 - 5.21
8 to 49 26 4.15 6.27 4.27 - 9.21
≥50 22 2.12 10.38 6.83 - 15.76
BCG-adjusted TST* (mm)
<5 28 27.91 1.00 0.69 - 1.45
5 to 9 19 3.94 4.82 3.07 - 7.56
10 to 14 13 3.02 4.30 2.50 - 7.40
≥15 26 2.83 9.19 6.26 - 13.49
*For participants with previous BCG vaccination (defined by self-report and scar inspection), 10mm was 
deducted from the quantitative TST result to adjust for the associated sensitisation to BCG (‘BCG-
adjusted TST’)
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S5: Sensitivity analysis (b): Sub-analyses among contacts and migrants
Supplementary Table 4: Estimates of incidence rates of TB by test strata according to risk group 
(contacts vs. migrants). IR = incidence rate; CI = confidence intervals.
CONTACTS
QFT-GIT (IU/mL) TB cases Person-years 
(1,000s)
IR (per 1,000) 95% CI
<0.35 22 16.08 1.37 0.90 - 2.08
0.35-0.69 5 0.90 5.55 2.31 - 13.34
0.7-3.99 18 2.01 8.97 5.65 - 14.23
≥4 15 1.11 13.53 8.16 - 22.45
T-SPOT.TB (spots)
<5 25 16.56 1.51 1.02 - 2.23
5 to 7 3 0.89 3.39 1.09 - 10.50
8 to 49 16 2.04 7.86 4.81 - 12.82
≥50 18 1.10 16.37 10.31 - 25.98
BCG-adjusted TST* (mm)
<5 22 15.15 1.45 0.96 - 2.21
5 to 9 11 2.21 4.99 2.76 - 9.01
10 to 14 12 1.80 6.66 3.78 - 11.74
≥15 21 1.76 11.96 7.80 - 18.34
MIGRANTS
QFT-GIT (IU/mL) TB cases Person-years 
(1,000s)
IR (per 1,000) 95% CI
<0.35 12 14.59 0.82 0.47 - 1.45
0.35-0.69 2 0.99 2.02 0.50 - 8.07
0.7-3.99 9 1.76 5.12 2.66 - 9.84
≥4 11 1.47 7.50 4.16 - 13.55
T-SPOT.TB (spots)
<5 8 13.10 0.61 0.31 - 1.22
5 to 7 0 0.64 0.00 -
8 to 49 14 2.08 6.74 3.99 - 11.37
≥50 9 0.99 9.12 4.75 - 17.53
BCG-adjusted TST* (mm)
<5 8 12.34 0.65 0.32 - 1.30
5 to 9 11 1.71 6.45 3.57 - 11.65
10 to 14 6 1.20 4.98 2.24 - 11.09
≥15 10 1.06 9.42 5.07 - 17.51
*For participants with previous BCG vaccination (defined by self-report and scar inspection), 10mm was 
deducted from the quantitative TST result to adjust for the associated sensitisation to BCG (‘BCG-
adjusted TST’)
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Supplementary Table 5: Sensitivity, specificity, positive predictive values and negative predictive values among contacts in UK PREDICT TB cohort, during 
three years’ follow-up with pre-specified test thresholds. CI = confidence interval; QFT-GIT = QuantiFERON Gold-In-Tube; TST = tuberculin skin test; n = 
numerator; N = denominator.
QFT-GIT (IU/mL) T-SPOT.TB (spots) BCG-adjusted TST* (mm)
≥0.35 ≥0.7 ≥4 ≥5 ≥8 ≥50 ≥5 ≥10 ≥15
Sensitivity n 31 27 10 32 29 14 38 28 17
N 51 51 51 53 53 53 57 57 57
Estimate 60.8% 52.9% 19.6% 60.4% 54.7% 26.4% 66.7% 49.1% 29.8%
95% CI (46.1-74.2) (38.5-67.1) (9.8-33.1) (46-73.5) (40.4-68.4) (15.3-40.3) (52.9-78.6) (35.6-62.7) (18.4-43.4)
Specificity n 2999 3169 3533 3074 3239 3610 2847 3270 3606
N 3740 3740 3740 3822 3822 3822 3945 3945 3945
Estimate 80.2% 84.7% 94.5% 80.4% 84.7% 94.5% 72.2% 82.9% 91.4%
95% CI (78.9-81.5) (83.5-85.9) (93.7-95.2) (79.1-81.7) (83.6-85.9) (93.7-95.2) (70.7-73.6) (81.7-84.1) (90.5-92.3)
Positive predictive value n 31 27 10 32 29 14 38 28 17
N 772 598 217 780 612 226 1136 703 356
Estimate 4.0% 4.5% 4.6% 4.1% 4.7% 6.2% 3.3% 4.0% 4.8%
95% CI (2.7-5.7) (3-6.5) (2.2-8.3) (2.8-5.7) (3.2-6.7) (3.4-10.2) (2.4-4.6) (2.7-5.7) (2.8-7.5)
Negative predictive value n 2999 3169 3533 3074 3239 3610 2847 3270 3606
N 3019 3193 3574 3095 3263 3649 2866 3299 3646
Estimate 99.3% 99.2% 98.9% 99.3% 99.3% 98.9% 99.3% 99.1% 98.9%
95% CI (99-99.6) (98.9-99.5) (98.4-99.2) (99-99.6) (98.9-99.5) (98.5-99.2) (99-99.6) (98.7-99.4) (98.5-99.2)
*For participants with previous BCG vaccination (defined by self-report and scar inspection), 10mm was deducted from the quantitative TST result to adjust for 
the associated sensitisation to BCG (‘BCG-adjusted TST’)
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Supplementary Table 6: Sensitivity, specificity, positive predictive values and negative predictive values among migrants in UK PREDICT TB cohort, 
during three years’ follow-up with pre-specified test thresholds. CI = confidence interval; QFT-GIT = QuantiFERON Gold-In-Tube; TST = tuberculin skin test 
; n = numerator; N = denominator.
QFT-GIT (IU/mL) T-SPOT.TB (spots) BCG-adjusted TST* (mm)
≥0.35 ≥0.7 ≥4 ≥5 ≥8 ≥50 ≥5 ≥10 ≥15
Sensitivity n 19 17 9 21 21 8 24 14 8
N 31 31 31 28 28 28 32 32 32
Estimate 61.3% 54.8% 29.0% 75.0% 75.0% 28.6% 75.0% 43.8% 25.0%
95% CI (42.2-78.2) (36-72.7) (14.2-48) (55.1-89.3) (55.1-89.3) (13.2-48.7) (56.6-88.5) (26.4-62.3) (11.5-43.4)
Specificity n 3065 3270 3629 2706 2838 3254 2600 2946 3193
N 3932 3932 3932 3451 3451 3451 3414 3414 3414
Estimate 78.0% 83.2% 92.3% 78.4% 82.2% 94.3% 76.2% 86.3% 93.5%
95% CI (76.6-79.2) (82-84.3) (91.4-93.1) (77-79.8) (80.9-83.5) (93.5-95) (74.7-77.6) (85.1-87.4) (92.6-94.3)
Positive predictive value n 19 17 9 21 21 8 24 14 8
N 886 679 312 766 634 205 838 482 229
Estimate 2.1% 2.5% 2.9% 2.7% 3.3% 3.9% 2.9% 2.9% 3.5%
95% CI (1.3-3.3) (1.5-4) (1.3-5.4) (1.7-4.2) (2.1-5) (1.7-7.5) (1.8-4.2) (1.6-4.8) (1.5-6.8)
Negative predictive value n 3065 3270 3629 2706 2838 3254 2600 2946 3193
N 3077 3284 3651 2713 2845 3274 2608 2964 3217
Estimate 99.6% 99.6% 99.4% 99.7% 99.8% 99.4% 99.7% 99.4% 99.3%
95% CI (99.3-99.8) (99.3-99.8) (99.1-99.6) (99.5-99.9) (99.5-99.9) (99.1-99.6) (99.4-99.9) (99-99.6) (98.9-99.5)
* For participants with previous BCG vaccination (defined by self-report and scar inspection), 10mm was deducted from the quantitative TST result to adjust for 
the associated sensitisation to BCG (‘BCG-adjusted TST’)
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Supplementary Figure 2:  Receiver operating characteristic curves for prediction of incident tuberculosis (TB) during three years’ follow-up among (a) contacts; 
and (b) migrants in UK PREDICT TB cohort, by quantitative QuantiFERON Gold-In-Tube (QFT-GIT), T-SPOT.TB and BCG-adjusted tuberculin skin test results. 
AUC = area under the curve. 
(a) (b)
  
Page 41 of 46  AJRCCM Articles in Press. Published on 11-December-2019 as 10.1164/rccm.201905-0969OC 
 Copyright © 2019 by the American Thoracic Society 
S6: Sensitivity analysis (c): Additional (fifth) stratum included for each diagnostic test
Supplementary Table 7: Tuberculosis (TB) incidence rates in ordinal strata including fifth stratum for 
quantitative results of each diagnostic test (≥8.00 IU/mL for QFT-GIT; ≥100 spots for T-SPOT.TB; 
≥20mm for BCG-adjusted TST). CI = confidence interval; QFT-GIT = QuantiFERON Gold-In-Tube; TST 
= tuberculin skin test; IR = incidence rate. 
QFT-GIT (IU/mL) TB cases Person-years 
(1,000s)
IR (per 1,000) 95% CI
<0.35 34 31.05 1.10 0.78 - 1.53
0.35-0.69 7 1.90 3.68 1.75 - 7.71
0.7-3.99 27 3.80 7.10 4.87 - 10.35
4-7.99 15 1.30 11.55 6.96 - 19.16
≥8 11 1.30 8.49 4.70 - 15.33
T-SPOT.TB (spots)
<5 33 30.07 1.10 0.78 - 1.54
5 to 7 3 1.54 1.95 0.63 - 6.06
8 to 49 30 4.15 7.23 5.06 - 10.35
50 to 99 6 1.18 5.07 2.28 - 11.28
≥100 21 0.94 22.42 14.62 - 34.38
BCG-adjusted TST* (mm)
<5 30 27.91 1.07 0.75 - 1.54
5 to 9 22 3.94 5.58 3.67 - 8.47
10 to 14 18 3.03 5.95 3.75 - 9.44
15 to 19 14 1.47 9.55 5.66 - 16.13
≥20 17 1.36 12.46 7.75 - 20.04
*For participants with previous BCG vaccination (defined by self-report and scar inspection), 10mm was 
deducted from the quantitative TST result to adjust for the associated sensitisation to BCG (‘BCG-
adjusted TST’)
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Supplementary Table 8: Sensitivity, specificity, positive predictive values and negative predictive values, during three years’ follow-up with additional test 
thresholds. CI = confidence interval; QFT-GIT = QuantiFERON Gold-In-Tube; TST = tuberculin skin test; n = numerator; N = denominator.
QFT-GIT ≥ 8 IU/mL T-SPOT.TB ≥ 100 spots BCG-adjusted TST* ≥ 20mm
Sensitivity n 9 16 12
N 82 81 89
Estimate 11.0% 19.8% 13.5%
(5.1-19.8) (11.7-30.1) (7.2-22.4)
Specificity n 7501 7181 7172
N 7755 7363 7445
Estimate 96.7% 97.5% 96.3%
(96.3-97.1) (97.1-97.9) (95.9-96.7)
Positive predictive value n 9 16 12
N 263 198 285
Estimate 3.4% 8.1% 4.2%
(1.6-6.4) (4.7-12.8) (2.2-7.2)
Negative predictive value n 7501 7181 7172
N 7574 7246 7249
Estimate 99.0% 99.1% 98.9%
(98.8-99.2) (98.9-99.3) (98.7-99.2)
*For participants with previous BCG vaccination (defined by self-report and scar inspection), 10mm was deducted from the quantitative TST result to adjust 
for the associated sensitisation to BCG (‘BCG-adjusted TST’)
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S7: Sensitivity analysis (d): TB incidence rates among participant with indeterminate test results
Supplementary Table 9: Tuberculosis (TB) incidence rates among subjects with indeterminate results. 
CI = confidence interval; QFT-GIT = QuantiFERON Gold-In-Tube; TST = tuberculin skin test; IR = 
incidence rate. 
TB cases Person-years 
(1,000s)
IR 
(per 1,000)
95% CI
Indeterminate QFT-GIT 3 0.58 5.21 1.69 - 16.17
Indeterminate T-SPOT.TB 2 0.60 3.32 0.84 - 13.29
S8: Sensitivity analysis (e): Quantitative TST results analysed without subtracting the 10mm 
deduction for participants who reported BCG vaccination
Supplementary Table 10: Tuberculosis (TB) incidence rates in ordinal TST strata without subtracting 
a 10mm deduction for participants who reported BCG vaccination. TST = tuberculin skin test; IR = 
incidence rate. 
Unadjusted TST
(mm)
TB cases Person-years 
(1,000s)
IR 
(per 1,000)
95% CI
<5 16 20.89 0.77 0.47 - 1.25
5 to 9 10 4.69 2.13 1.15 - 3.97
10 to 14 10 4.81 2.08 1.12 - 3.86
≥15 65 7.33 8.87 6.96 - 11.31
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S9: Sensitivity analysis (f): Sensitivity, specificity and predictive values recalculated for a fixed follow-up period of six months
Supplementary Table 11: Sensitivity, specificity, positive predictive values and negative predictive values in UK PREDICT TB cohort, with follow-up limited to 
six months, using pre-specified test thresholds. CI = confidence interval; QFT-GIT = QuantiFERON Gold-In-Tube; TST = tuberculin skin test ; n = numerator; N 
= denominator.
QFT-GIT (IU/mL) T-SPOT.TB (spots) BCG-adjusted TST* (mm)
≥0.35 ≥0.7 ≥4 ≥5 ≥8 ≥50 ≥5 ≥10 ≥15
Sensitivity n 26 22 13 33 31 17 39 29 18
N 45 45 45 44 44 44 49 49 49
Estimate 57.8% 48.9% 28.9% 75.0% 70.5% 38.6% 79.6% 59.2% 36.7%
95% CI (42.2-72.3) (33.7-64.2) (16.4-44.3) (59.7-86.8) (54.8-83.2) (24.4-54.5) (65.7-89.8) (44.2-73) (23.4-51.7)
Specificity n 6618 7019 7829 6278 6595 7487 5758 6575 7194
N 8394 8394 8394 7913 7913 7913 7783 7783 7783
Estimate 78.8% 83.6% 93.3% 79.3% 83.3% 94.6% 74.0% 84.5% 92.4%
95% CI (78-79.7) (82.8-84.4) (92.7-93.8) (78.4-80.2) (82.5-84.2) (94.1-95.1) (73-75) (83.7-85.3) (91.8-93)
Positive predictive value n 26 22 13 33 31 17 39 29 18
N 1802 1397 578 1668 1349 443 2064 1237 607
Estimate 1.4% 1.6% 2.2% 2.0% 2.3% 3.8% 1.9% 2.3% 3.0%
95% CI (0.9-2.1) (1-2.4) (1.2-3.8) (1.4-2.8) (1.6-3.2) (2.3-6.1) (1.3-2.6) (1.6-3.3) (1.8-4.6)
Negative predictive value n 6618 7019 7829 6278 6595 7487 5758 6575 7194
N 6637 7042 7861 6289 6608 7514 5768 6595 7225
Estimate 99.7% 99.7% 99.6% 99.8% 99.8% 99.6% 99.8% 99.7% 99.6%
95% CI (99.6-99.8) (99.5-99.8) (99.4-99.7) (99.7-99.9) (99.7-99.9) (99.5-99.8) (99.7-99.9) (99.5-99.8) (99.4-99.7)
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S10: Sensitivity analysis (g): Multivariable analysis of association between quantitative test results and incident TB
Supplementary Table 12: Associations between quantitative test results and incident TB in multivariable Poisson models adjusted for age, gender, ethnicity, 
country of birth and indication for screening (recent contact vs. migration). CI = confidence interval; QFT-GIT = QuantiFERON Gold-In-Tube; TST = tuberculin 
skin test. P values for categorical variables with multiple levels indicate likelihood ratio tests. 
 IRR 95% CI p  IRR 95% CI p  IRR 95% CI p
QFT-GIT result (IU/mL)    T-SPOT.TB result (spots)    BCG-adjusted TST (mm)    
<0.35 1 (ref)   <5 1 (ref)   <5 1 (ref)   
0.35-0.69 3.61 1.59 - 8.16 <0.0001 5 to 7 1.85 0.57 - 6.05 <0.0001 5 to 9 5.12 2.95 - 8.9 <0.0001
0.7-3.99 6.93 4.15 - 11.58  8 to 49 7.51 4.51 - 12.5  10 to 14 5.66 3.13 - 10.22  
≥4 10.36 6.15 - 17.44  ≥50 13.41 7.91 - 22.73  ≥15 10.30 6.19 - 17.12  
Age    Age    Age    
≤35 1 (ref)   ≤35 1 (ref)   ≤35 1 (ref)   
>35 0.65 0.42 - 0.99 0.046 >35 0.58 0.38 - 0.91 0.017 >35 0.71 0.47 - 1.07 0.10
            
Gender    Gender    Gender    
Male 1 (ref)   Male 1 (ref)   Male 1 (ref)   
Female 1.10 0.73 - 1.65 0.66 Female 1.07 0.71 - 1.62 0.75 Female 1.03 0.7 - 1.53 0.88
            
Ethnicity    Ethnicity    Ethnicity    
White 1 (ref)   White 1 (ref)   White 1 (ref)   
South Asian 0.98 0.5 - 1.94 0.68 South Asian 0.88 0.44 - 1.74 0.69 South Asian 1.03 0.52 - 2.06 0.95
Black African or Caribbean 0.68 0.3 - 1.54  Black African or Caribbean 0.66 0.3 - 1.47  Black African or Caribbean 0.87 0.4 - 1.91  
Other 0.89 0.4 - 1.97  Other 0.75 0.33 - 1.69  Other 1.00 0.45 - 2.21  
            
UK born    UK born    UK born    
No 1 (ref)   No 1 (ref)   No 1 (ref)   
Yes 0.96 0.52 - 1.78 0.90 Yes 0.96 0.51 - 1.82 0.91 Yes 0.78 0.42 - 1.44 0.43
            
Contact or migrant    Contact or migrant    Contact or migrant    
Migrant 1 (ref)   Migrant 1 (ref)   Migrant 1 (ref)   
Contact 1.90 1.2 - 3.02 0.007 Contact 1.98 1.24 - 3.18 0.004 Contact 1.47 0.94 - 2.3 0.09
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